BioNxt Solutions (OTCMKTS:BNXTF) Trading Down 2.9% - Should You Sell?

Key Points

• BioNxt Solutions shares fell by 2.9% to $0.63 with only 100 shares traded, a significant decline from the average daily volume of 2,644 shares.
• The company reported a market capitalization of $73.44 million and a P/E ratio of -15.86, indicating that it is currently operating at a loss.
• BioNxt specializes in drug formulations and delivery systems for neurological medications and diagnostic tests, including COVID-19 tests and oral biosensors for pathogen detection.

Shares of BioNxt Solutions Inc. (OTCMKTS:BNXTF - Get Free Report) were down 2.9% during mid-day trading on Wednesday . The company traded as low as $0.63 and last traded at $0.63. Approximately 100 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 2,644 shares. The stock had previously closed at $0.65.

BioNxt Solutions Stock Performance

The firm has a market capitalization of $73.44 million, a P/E ratio of -15.86 and a beta of 0.85. The business has a fifty day moving average of $0.61 and a 200-day moving average of $0.45.

BioNxt Solutions (OTCMKTS:BNXTF - Get Free Report) last issued its quarterly earnings results on Thursday, August 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About BioNxt Solutions

BioNxt Solutions Inc engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.